title: Fluorouracil, leucovorin and irinotecan combined with intra-arterial hepatic infusion of drug-eluting beads preloaded with irinotecan in unresectable colorectal liver metastases: side effects and results of a concomitant treatment schedule. Clinical investigation.
abstract: OBJECTIVE
  Safety evaluation of concomitant systemic chemotherapy and liver chemoembolization in patients with colorectal cancer.
  
  
  METHODS
  Seven patients with metastases confined to the liver were included and stratified into two groups, depending of dosage of systemic chemotherapy. The first group received systemic chemotherapy (FOLFIRI) with 20% dose reduction, and the second group received the full dose of the same chemotherapy. In both groups, chemoembolization of liver metastases with drug-eluting bead irinotecan (DEBIRI) was performed following the application of systemic chemotherapy. The toxicity profiles of the two groups were compared.
  
  
  RESULTS
  Of the 7 patients included, 4 received the reduced systemic chemotherapy dose and 3 received the full chemotherapy dose. DEBIRI was performed in all 7 patients. The main toxicities observed in the reduced chemotherapy dose group were leukopenia (25%), anorexia (75%), diarrhea (25%), vomiting (25%), right upper abdominal quadrant pain (100%) and elevated serum amylase level (25%). Main toxicities observed in the full chemotherapy dose group were anorexia (66.6%), vomiting (33.3%), right upper abdominal quadrant pain (100%), and elevated serum amylase level (66.6%). There were no significant differences between the two groups ( P = 0.78541).
  
  
  CONCLUSIONS
  Patients with isolated liver metastases from a colorectal primary can safely be treated with DEBIRI chemoembolization and a full dose of systemic chemotherapy (FOLFIRI).
authors.forename: Domina
authors.initials: D
authors.lastname: Kekez
authors.forename: Sasa
authors.initials: S
authors.lastname: Badzek
authors.forename: Juraj
authors.initials: J
authors.lastname: Prejac
authors.forename: Irma
authors.initials: I
authors.lastname: Gorsic
authors.forename: Hilda
authors.initials: H
authors.lastname: Golem
authors.forename: Niksa
authors.initials: N
authors.lastname: Librenjak
authors.forename: Drazen
authors.initials: D
authors.lastname: Perkov
authors.forename: Ranko
authors.initials: R
authors.lastname: Smiljanic
authors.forename: Stjepko
authors.initials: S
authors.lastname: Plestina
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D016461:Chemoembolization, Therapeutic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D004337:Drug Carriers / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D016896:Treatment Outcome
chemical_list: D003692:Delayed-Action Preparations; D004337:Drug Carriers; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin